{
    "body": "Which two drugs are included in the Harvoni pill?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27480956", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25837989", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25516691", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25859119", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26357632", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26327920", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26312999", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27606041", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25937625", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25850880", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25987834", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27193156", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26788571", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27276081"
    ], 
    "ideal_answer": [
        "Harvoni contains 400 mg sofosbuvir and 90 mg ledipasvir. It used for treatment of hepatitis C virus infection."
    ], 
    "exact_answer": [
        [
            "sofosbuvir"
        ], 
        [
            "ledipasvir"
        ]
    ], 
    "type": "list", 
    "id": "5896deff78275d0c4a000013", 
    "snippets": [
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 123, 
            "text": "Will Sofosbuvir/Ledipasvir (Harvoni) Be Cost-Effective and Affordable for Chinese Patients Infected with Hepatitis C Virus?", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27276081", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 1216, 
            "offsetInEndSection": 1435, 
            "text": "The developed method was applied to the analysis of the two drugs after a single oral administration of Harvoni 400/90 mg film-coated tablets containing 400 mg sofosbuvir and 90 mg ledipasvir to four healthy volunteers.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27480956", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 245, 
            "text": "After the introductions of sofosbuvir (Sovaldi) and ledipasvir plus sofosbuvir (Harvoni) for the treatment of hepatitis C, employers have become very sensitive to new, and especially unforeseen, factors that significantly raise healthcare costs.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27606041", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 212, 
            "text": "The single-tablet regimen of the hepatitis C virus (HCV) NS5A inhibitor ledipasvir and the HCV NS5B polymerase inhibitor sofosbuvir (ledipasvir/sofosbuvir; Harvoni(\u00ae)) was recently approved in the US and the EU. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25837989", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 83, 
            "text": "Ledipasvir/Sofosbuvir (harvoni): improving options for hepatitis C virus infection.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25859119", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 83, 
            "text": "Ledipasvir/sofosbuvir (Harvoni): improving options for hepatitis C virus infection.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25859119", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 677, 
            "offsetInEndSection": 936, 
            "text": "Also reviewed were recent practice guidelines on the management of HCV infections, prescribing information on all HCV drugs approved by the US Food and Drug Administration, and health technology assessments of Sovaldi\u00ae and Harvoni(TM) (sofosbuvir/ledipasvir).", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25850880", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 84, 
            "text": "Ledipasvir/Sofosbuvir (harvoni): improving options for hepatitis C virus infection.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25859119", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 851, 
            "offsetInEndSection": 1104, 
            "text": "This review will summarize the data regarding these interferon-free regimens, including Gilead's Harvoni (sofosbuvir/ledipasvir), AbbVie's Viekira Pak (paritaprevir/ritonavir/ombitasvir with dasabuvir), and Janssen's Olysio (simeprevir) with sofosbuvir.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26327920", 
            "endSection": "abstract"
        }
    ]
}